Vident Advisory LLC Sells 48,983 Shares of CVS Health Co. (NYSE:CVS)

Vident Advisory LLC lowered its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 59.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,233 shares of the pharmacy operator's stock after selling 48,983 shares during the quarter. Vident Advisory LLC's holdings in CVS Health were worth $1,492,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Coppell Advisory Solutions LLC lifted its position in CVS Health by 17.3% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator's stock valued at $56,000 after purchasing an additional 189 shares during the last quarter. EagleClaw Capital Managment LLC raised its stake in shares of CVS Health by 3.4% in the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock valued at $275,000 after acquiring an additional 200 shares during the period. Manchester Capital Management LLC raised its stake in shares of CVS Health by 4.8% in the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock valued at $200,000 after acquiring an additional 204 shares during the period. Angeles Investment Advisors LLC raised its stake in shares of CVS Health by 3.7% in the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock valued at $256,000 after acquiring an additional 204 shares during the period. Finally, Rogco LP raised its stake in shares of CVS Health by 3.2% in the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock valued at $303,000 after acquiring an additional 210 shares during the period. Institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of CVS stock traded up $1.90 on Wednesday, hitting $63.24. 3,131,147 shares of the stock traded hands, compared to its average volume of 11,282,193. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The company has a market capitalization of $80.00 billion, a PE ratio of 17.29, a PEG ratio of 0.98 and a beta of 0.60. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $72.51. The company's fifty day moving average is $65.86 and its 200 day moving average is $59.46.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm's revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.31 EPS. On average, equities research analysts predict that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 annualized dividend and a dividend yield of 4.21%. CVS Health's payout ratio is 63.48%.

Insider Transactions at CVS Health

In other news, SVP James David Clark sold 7,513 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at $556,941.90. This represents a 47.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.22% of the company's stock.

Wall Street Analyst Weigh In

CVS has been the topic of several recent analyst reports. Royal Bank of Canada raised their price target on shares of CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research note on Monday, May 5th. Wall Street Zen raised shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Argus set a $77.00 price target on shares of CVS Health in a report on Tuesday, February 18th. Edward Jones raised shares of CVS Health from a "hold" rating to a "buy" rating in a report on Thursday, January 30th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $74.94.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.